The use of immunotherapy agents is rising for treatment of esophageal cancers, explains Nataliya Uboha, MD, PhD, assistant professor (CHS), Hematology, Medical Oncology and Palliative Care. 

Dr. Uboha recently discussed the topic on the American Society for Clinical Oncology Daily News podcast, which provides information for oncology professionals. 

She explained that of the two types of esophageal cancer, adenocarcinoma and squamous cell carcinoma, adenocarcinoma of the esophagus is on the rise in the US but squamous cell carcinoma predominates globally. 

"Metastatic disease is incurable in virtually all patients," said Dr. Uboha. However, after progression on first-line chemotherapy, second-line and more recently third-line immunotherapy options now exist, with additional clinical trials currently underway. 

Resources:

• "Gastrointestinal Cancers: Dr. Nataliya V. Uboha," ASCO Daily News, January 17, 2018